Patent revocations in India may spread to other regions (or not) say legal experts
This article was originally published in Scrip
Patent revocations in a string of high-profile cases in India in 2012, including those concerning Pfizer’s Sutent (sunitinib malate) and Roche’s Pegasys (pegylated interferon alfa-2a) may be factored in as important reference points by other developing nations in future, some legal experts warn.
You may also be interested in...
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.